Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-26T22:52:45.917Z Has data issue: false hasContentIssue false
  • English
  • Français

Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers’ Information Sources

Published online by Cambridge University Press:  17 March 2022

Shunsuke Takada Open the ORCID record for Shunsuke Takada [Opens in a new window]  and
Mamoru Narukawa
Shunsuke Takada*
Affiliation:
Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan Daiichi Sankyo Co., Ltd., Tokyo, Japan
Mamoru Narukawa
Affiliation:
Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan
*
*Author for correspondence: Shunsuke Takada, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

The National Institute for Health and Care Excellence’s (NICE) method guide for technology appraisals (TAs) encourages medicine manufacturers to use the EuroQol 5 Dimensions (EQ-5D) in relevant clinical trials to obtain utility values; however, the EQ-5D may have low sensitivity when compared to disease-specific measures. This study investigated whether the NICE TA committee’s acceptance of manufacturer-proposed utility values is dependent on the manufacturers’ sources of the utility values.

Methods

Using publicly available data for 2011–2020, we identified 136 single TAs of cancer medicines, the health-related quality-of-life-measures used in relevant clinical trials, manufacturers’ sources of utility values, and the NICE TA committee’s acceptance of these values. Fisher’s exact tests were performed to compare the acceptability of different value sources and reasons for non-acceptance.

Results

The number of appraisals for which the EQ-5D in the relevant clinical trials was the source of the manufacturer-proposed utility values increased continuously over time. The TA committee’s acceptance of values was not dependent on the information source. In cases where a submission for which the information source was the EQ-5D was rejected, the reason was generally related to inappropriate values for the UK population or inappropriate data adjustment, not data reliability.

Conclusions

Our results demonstrated that according with the NICE’s method guide regarding utility values does not guarantee acceptance by the TA committee. Manufacturers must consider in advance possible differences between their clinical trials and clinical practice in the UK and refine plans for EQ-5D measurement in order to obtain convincing evidence.

Keywords

Technology assessmentBiomedicalHealthcare economics and organizationsEnglandQuality-of-life
Type
Assessment
Information
International Journal of Technology Assessment in Health Care , Volume 38 , Issue 1 , 2022 , e25
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

National Institute for Health and Care Excellence [Internet] (2018). Guide to the processes of technology appraisal. Available at: https://www.nice.org.uk/process/pmg19/chapter/foreword. Accessed 2022.Google Scholar
Mehrez, A, Gafni, A (1989) Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 9, 142–9.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence [Internet] (2013) Guide to the methods of technology appraisal. Available at: https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed 2022.Google Scholar
Devlin, NJ, Brooks, R (2017) EQ-5D and the EuroQol group: Past, present and future. Appl Health Econ Health Policy 15, 127–37.CrossRefGoogle ScholarPubMed
Christiansen, ASJ, Møller, MLS, Kronborg, C, et al. (2021) Comparison of the three-level and the five-level versions of the EQ-5D. Eur J Health Econ 22, 621–8.CrossRefGoogle ScholarPubMed
Aaronson, NK, Ahmedzai, S, Bergman, B, et al. (1993) The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85, 365–76.CrossRefGoogle ScholarPubMed
Cella, DF, Tulsky, DS, Gray, G, et al. (1993) The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11, 570–9.CrossRefGoogle ScholarPubMed
Reed, E, Kössler, I, Hawthorn, J (2012) Quality of life assessments in advanced breast cancer: Should there be more consistency? Eur J Cancer Care 21, 565–80.CrossRefGoogle ScholarPubMed
Rose, M, Rice, S, Craig, D (2018) Does methodological guidance produce consistency? A review of methodological consistency in breast cancer utility value measurement in NICE single technology appraisals. Pharmacoecon Open 2, 97–107.CrossRefGoogle ScholarPubMed
Adlard, N, Kinghorn, P, Frew, E (2014) Is the UK NICE “reference case” influencing the practice of pediatric quality-adjusted life-year measurement within economic evaluations? Value Health 17, 454–61.CrossRefGoogle ScholarPubMed
Tosh, JC, Longworth, LJ, George, E (2011) Utility values in National Institute for Health and Clinical Excellence (NICE) technology appraisals. Value Health 14, 102–9.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence [Internet] (2020) Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. Technology appraisal guidance [TA632]. Available at: https://www.nice.org.uk/guidance/ta632. Accessed 2022.Google Scholar
Tappenden, P, Chilcott, JB (2014) Avoiding and identifying errors and other threats to the credibility of health economic models. Pharmacoeconomics 32, 967–79.CrossRefGoogle Scholar
National Institute for Health and Care Excellence [Internet] (2016) Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. Technology appraisal guidance [TA411]. Available at: https://www.nice.org.uk/guidance/ta411. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2017) Cabozantinib for previously treated advanced renal cell carcinoma. Technology appraisal guidance [TA463]. Available at: https://www.nice.org.uk/guidance/ta463. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2017) Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. Technology appraisal guidance [TA496]. Available at: https://www.nice.org.uk/guidance/ta496. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet]. (2017) Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. Technology appraisal guidance [TA660]. Available at: https://www.nice.org.uk/guidance/ta660. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2020) Reviewing our methods for health technology evaluation: Consultation. Available at: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/chte-methods-consultation. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2014) Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. Technology appraisal guidance [TA307]. Available at: https://www.nice.org.uk/guidance/ta307. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2020) Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. Technology appraisal guidance [TA649]. Available at: https://www.nice.org.uk/guidance/ta649. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2020) Larotrectinib for treating NTRK fusion-positive solid tumours. Technology appraisal guidance [TA630]. Available at: https://www.nice.org.uk/guidance/ta630. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2019) Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. Technology appraisal guidance [TA612]. Available at: https://www.nice.org.uk/guidance/ta612. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2020) Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Technology appraisal guidance [TA639]. Available at: https://www.nice.org.uk/guidance/ta639. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2015) Bortezomib for previously untreated mantle cell lymphoma. Technology appraisal guidance [TA370]. Available at: https://www.nice.org.uk/guidance/ta370. Accessed 2022.Google Scholar
National Institute for Health and Care Excellence [Internet] (2019) Enzalutamide for hormone-relapsed non-metastatic prostate cancer. Technology appraisal guidance [TA580]. Available at: https://www.nice.org.uk/guidance/ta580. Accessed 2022.Google Scholar
Supplementary material: File

Takada and Narukawa supplementary material

Takada and Narukawa supplementary material

Download Takada and Narukawa supplementary material(File)
File 50.8 KB